In order to plan an adequate adjuvant therapy in patients with primary breast cancer (Table 4), pathology reports must include in all cases the expression and levels of ER-alpha, PR, HER2 and Ki-67, in addition to histological grade, to assist prognosis and to establish current therapeutic options available, including hormone therapy, chemotherapy and anti-HER2 therapy. The gene discussed is ERBB2; the disease is breast cancer.